Eiger BioPharmaceuticals Культура компании

Dr. Joanne M. J. Quan, M.D., has been the Chief Medical Officer of Eiger BioPharmaceuticals, Inc. since March 22, 2016. Dr. Quan served as Vice President of Clinical and Regulatory Affairs at Bayhill Therapeutics, Inc. since November 2008. From 2005 to 2008, Dr. Quan served as Senior Director of Clinical Development at Alza Corporation (Johnson and Johnson). She served as Vice President, New Product Clinical Development at InterMune. Previously, she was Vice President, Clinical Development at Arena Pharmaceuticals and led the collaboration with Eisai for lorcaserin (BELVIQ) as well as pipeline planning for Arena, including initiation of a Phase 2 program in Pulmonary Arterial Hypertension (PAH). She held various positions in Clinical Research at Genentech from 2000 to 2005 and at PathoGenesis Corporation from 1996 to 2000. She served as Board of Trustee of Maimonides Medical Center. Dr. Quan held scientific, clinical and regulatory positions of increasing responsibility at Bayhill Therapeutics, Alza (Johnson and Johnson), Genentech and PathoGenesis. She has led multiple successful collaborations and project teams, several IND/CTA submissions and designed, conducted and analyzed numerous Phase 1-4 clinical trials in multiple therapeutic areas, many in orphan diseases. She completed her training in Pulmonary-Critical Care Medicine at the University of Washington, Seattle and Internal Medicine at Massachusetts General Hospital. Dr. Quan received a BA in Molecular Biology from the University of California, Berkeley and an MD from the Stanford University.

Mr. James A. Welch, also known as Jim, MBA, serves as a Director of Human Resources at Guardian Industries Corp. Mr. Welch has been Chief Financial Officer of Eiger BioPharmaceuticals, Inc. since March 22, 2016. He serves as Financial Controller at VIMOC Technologies, Inc. He served as Chief Financial Officer, Vice President and Corporate Controller at Beluga Composites Corporation since July 1997 and its Secretary and Treasurer since June 1997. Over 30 years of experience in young, entrepreneurial companies with over 20 years in life sciences companies as Chief Financial Officer. Mr. Welch have extensive knowledge and experience in fund raising for both private and public including two IPOs. He served as Chief Financial Officer, Principal Accounting Officer, Vice President and Secretary at Rigel Pharmaceuticals, Inc. since October 2001. He served as Chief Financial Officer at Cerimon Pharmaceuticals, Inc. since June 2006. He served as Chief Financial & Accounting Officer at Virobay Inc. since June 20, 2014 and also served as its Senior Vice President. He served as Chief Financial Officer at AcelRx Pharmaceuticals, Inc. from October 1, 2010 to March 2014 and Principal Accounting Officer until March 2014. Mr. Welch holds an M.B.A. from Washington State University and a B.A. in Business Administration from Whitworth College.

Dr. Jeffrey S. Glenn, M.D., Ph.D., is an Assistant Professor of Medicine at Stanford University School of Medicine. Dr. Glenn is a Founder, Consultant and Scientific Advisor of Eiger BioPharmaceuticals, Inc. He serves as Scientific Advisor at Antipodean Pharmaceuticals, Inc. He serves as Director of the Center for Hepatitis & Liver Tissue Engineering at Stanford University. He is the recipient of numerous Research & Clinical Awards including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research. He serves as a Scientific Advisor at Eiger BioPharmaceuticals, Inc. and has been its Director since March 22, 2016. He served as a Member of Clinical & Science Advisory Board of Presidio Pharmaceuticals, Inc. Dr. Glenn received his Undergraduate Degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization and both a PhD in Biochemistry and Biophysics and MD from the University of California, San Francisco Medical Scientist Training Program. Dr. Glenn completed an Internship and Residency in Internal Medicine, as well as a Fellowship in Gastroenterology at Stanford University's School of Medicine.

Evan Loh serves as the Director for Eiger BioPharmaceuticals, Inc.. Evan started at Eiger BioPharmaceuticals, Inc. in September of 2017. Evan is based in the Greater Philadelphia Area.

Ingrid Choong serves as the VP, Investor Relations and Corporate Development for Eiger BioPharmaceuticals, Inc.. Ingrid started at Eiger BioPharmaceuticals, Inc. in March of 2018. Ingrid is based in the San Francisco Bay Area.

Rich Franco serves as the VP, Clinical Strategy for Eiger BioPharmaceuticals, Inc.. Rich started at Eiger BioPharmaceuticals, Inc. in March of 2016. Rich is based in the Raleigh-Durham, North Carolina Area.

Joanne Quan serves as the Chief Medical Officer for Eiger BioPharmaceuticals, Inc.. Joanne started at Eiger BioPharmaceuticals, Inc. in December of 2015. Joanne is based in the San Francisco Bay Area.

Jim Shaffer serves as the Chief Business Officer for Eiger BioPharmaceuticals, Inc.. Jim started at Eiger BioPharmaceuticals, Inc. in August of 2014. Jim is based in the Raleigh-Durham, North Carolina Area.

David Apelian serves as the Chief Operations Officer and Executive Medical Officer of Eiger BioPharmaceuticals, Inc.. David started at Eiger BioPharmaceuticals, Inc. in January of 2018. David currently resides in the Greater New York City Area.